从指挥控制到生命周期监管:在中国制药立法中平衡创新和安全
Jing Zhang1, Shuchen Tang1, Pengqing Sun1
1School of Law, Tsinghua University, Beijing 100084, China.
Healthcare (Basel, Switzerland)
|March 28, 2025
概括
中国中国中国中国.
科学领域:
- 药品监管事务 药品监管事务
- 药物安全和创新政策 药物安全和创新政策
- 全球卫生治理全球卫生治理
背景情况:
- 中国的制药监管正在从命令控制模式转变为生命周期监管.
- 这一转型旨在平衡药物安全,创新和可访问性.
- 该研究考察了这些监管改革的演变,成就和挑战.
研究的目的:
- 系统地检查中国制药监管框架的演变.
- 分析中国监管改革的成就和挑战.
- 为全球制药治理提供见解.
主要方法:
- 混合方法方法:历史分析,政策文本挖掘,案例研究.
- 自1949年以来审查了法律和法规,包括COVID-19疫苗的批准.
- 与美国FDA和欧盟EMA框架进行比较分析.
主要成果:
- 中国的监管演变分为四个阶段:新兴,基础,深化改革和生命周期监管.
- 2019年药物管理法制度化了风险管理和生命周期监督.
- 里程碑包括疫苗管理法 (2019) 和更严格的处罚 (2020).
结论:
- 中国的生命周期法规显示出协调安全和创新的潜力,改善了API出口合规性和更快地批准突破性疗法.
- 挑战包括不均的执法,有条件批准的紧张关系和供应链依赖.
- 调查结果为发展中国家提供了监管改革的教训.
相关概念视频
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


